Announcements Trials
Browse Landscape

Phase

Phase 3 28Phase 2 23Phase NA 3Phase 1 3Phase 1/2 2Phase 2/3 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 39Lymphoid 38Myeloid 10Plasma cell 3Dermatologic 3Sarcoma 2CNS 2Breast 2Other neoplasm 1Other 1Head & Neck 1Classical hematology 1

Conditions

Breast Neoplasms 2Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Trastuzumab 71Paclitaxel 63Cyclophosphamide 56pembrolizumab 53Fulvestrant 42Carboplatin 40Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 19Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Methotrexate × Breast × Clear all
NCT00616122 2020-01-13

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

University of California, San Francisco

Phase 1/2 Terminated
32 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00397501 2017-04-21

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

OHSU Knight Cancer Institute

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡